Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis

Journal of Clinical Microbiology

Volumn 47, Issue 5, 2009, Pages 1613-

  Cunha, Burke A ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL STRAIN; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG URINE LEVEL; HUMAN; KLEBSIELLA PNEUMONIAE; LETTER; NAUSEA; PLASMA HALF LIFE; PRIORITY JOURNAL; UROSEPSIS; VOMITING;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MINOCYCLINE; SEPSIS; SERUM; URINARY TRACT INFECTIONS; URINE;

ACINETOBACTER BAUMANNII; KLEBSIELLA PNEUMONIAE;

EID: 66149085768     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00404-09     Document Type: Letter

References (12)

1. Agwuh, K. N., and A. MacGowan. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother. 58:256-265. (Pubitemid 44294934)
2. Cunha, B. A. 2007. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug resistant gram-negative bacteremias. J. Chemother. 19:232-233. (Pubitemid 46697747)
3. Cunha, B. A. 2009. Antibiotic essentials, 8th ed. Jones & Barlett, Sudbury, MA.
4. Cunha, B. A., P. D. Domenico, and C. B. Cunha. 2005. Pharmacodynamics of doxycycline. Clin. Microbiol. Infect. Dis. 52:163-164.
5. Cunha, B. A., B. McDermott, and S. Nausheen. 2008. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J. Chemother. 19:753-754.
6. Curcio, D. 2008. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J. Clin. Microbiol. 46:1892-1893.
7. Krueger, W. A., A. Volkhard, A. J. Kempf, et al. 2008. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-β-lactamase- producing Escherichia coli. J. Clin. Microbiol. 46:817-820.
8. MacGowan, A. P. 2008. Tigecycline pharmacokinetic/pharmacodynamic update. J. Antimicrob. Chemother. 62:11-16.
9. Noviello, S., F. Ianniello, S. Leone, et al. 2008. In vitro activity of tigecycline: MICS, MBCs, time-kill curves and post-antibiotic effect. J. Chemother. 20:577-580.
10. Rodvold, K. A., M. H. Gotfried, M. Cwik, et al. 2006. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58:1221-1229.
11. Slover, C. M., K. A. Rodvold, and L. H. Danziger. 2007. Tigecycline: a novel broad-spectrum antimicrobial. Ann. Pharmacother. 41:965-972.
12. Swoboda, S., M. Ober, C. Hainer, et al. 2008. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J. Antimicrob. Chemother. 61:729-733.